DataSheet1_Therapeutic potential of compounds targeting SARS-CoV-2 helicase.docx

The economical and societal impact of COVID-19 has made the development of vaccines and drugs to combat SARS-CoV-2 infection a priority. While the SARS-CoV-2 spike protein has been widely explored as a drug target, the SARS-CoV-2 helicase (nsp13) does not have any approved medication. The helicase shares 99.8% similarity with its SARS-CoV-1 homolog and was shown to be essential for viral replication. This review summarizes and builds on existing research on inhibitors of SARS-CoV-1 and SARS-CoV-2 helicases. Our analysis on the toxicity and specificity of these compounds, set the road going forward for the repurposing of existing drugs and the development of new SARS-CoV-2 helicase inhibitors.

COVID-19对经济和社会的影响使得研发疫苗和药物以应对SARS-CoV-2感染成为当务之急。尽管SARS-CoV-2刺突蛋白已被广泛研究作为药物靶点，但SARS-CoV-2解旋酶（nsp13）尚未有任何批准的药物。解旋酶与SARS-CoV-1的同源物具有99.8%的相似性，并被证实对于病毒复制至关重要。本综述总结了关于SARS-CoV-1和SARS-CoV-2解旋酶抑制剂的现有研究，并在此基础上进行拓展。我们对这些化合物的毒性和特异性的分析，为现有药物的重新利用和新型SARS-CoV-2解旋酶抑制剂的研发指明了道路。